Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastases
AbstractLeiomyoma is the most prevalent benign tumor of the female reproductive system. Benign metastasizing leiomyoma (BML) is a rare phenomenon that presents at distant sites, typically the lungs, exhibiting histopathological features similar to the primary uterine tumor in the absence of malignancy features in both. Fumarate hydratase-deficient uterine leiomyoma (FH-d UL) is an uncommon subtype among uterine smooth muscle tumors (0.5 –2%), showing distinctive histomorphology andFH inactivation. The majority of FH-d ULs are sporadic, caused by somaticFH inactivation, while a minority of cases occur in the context of th...
Source: Virchows Archiv - April 20, 2024 Category: Pathology Source Type: research
A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma
ConclusionThis study suggests that autologous RAK cell immunotherapy is safe and has clinical activity in previously treated mRCC patients. The improvement in peripheral blood immune profiling after RAK cell infusion highlights its potential as a cancer treatment. Further investigation is necessary to understand its clinical utility. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - April 20, 2024 Category: Cancer & Oncology Source Type: research
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2444. Online ahead of print.ABSTRACTCancer remains a significant global health challenge, and despite remarkable advancements in therapeutic strategies, poor tolerability of drugs (causing dose reduction/interruptions) and/or the emergence of drug resistance are major obstacles to successful treatment outcomes. Metastatic renal cell carcinoma (mRCC) accounts for 2% of global cancer diagnoses and deaths. Despite the initial success of targeted therapies in mRCC, challenges remain to overcome drug resistance that limits the long-term efficacy of these treatments. Our analysis ...
Source: The Journal of Clinical Pharmacology - April 19, 2024 Category: Drugs & Pharmacology Authors: Anita Moein Jin Y Jin Matthew R Wright Harvey Wong Source Type: research
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2444. Online ahead of print.ABSTRACTCancer remains a significant global health challenge, and despite remarkable advancements in therapeutic strategies, poor tolerability of drugs (causing dose reduction/interruptions) and/or the emergence of drug resistance are major obstacles to successful treatment outcomes. Metastatic renal cell carcinoma (mRCC) accounts for 2% of global cancer diagnoses and deaths. Despite the initial success of targeted therapies in mRCC, challenges remain to overcome drug resistance that limits the long-term efficacy of these treatments. Our analysis ...
Source: The Journal of Clinical Pharmacology - April 19, 2024 Category: Drugs & Pharmacology Authors: Anita Moein Jin Y Jin Matthew R Wright Harvey Wong Source Type: research
Renal cell carcinoma with fibromyomatous stroma: A uncommon and rare case
Asian J Surg. 2024 Apr 18:S1015-9584(24)00646-8. doi: 10.1016/j.asjsur.2024.04.014. Online ahead of print.NO ABSTRACTPMID:38641536 | DOI:10.1016/j.asjsur.2024.04.014 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - April 19, 2024 Category: Surgery Authors: Yuan Zhao Bo Tao Yunpeng He Lijun Wang Source Type: research
Integrated Bioinformatics and Experimental Validation to Identify a Disulfidptosis-Related lncRNA Model for Prognostic Prediction in Papillary Renal Cell Carcinoma
CONCLUSION: This study successfully established and validated a novel disulfidptosis-related prediction model. The findings suggest the potential involvement of immune-related pathways in lncRNA signature-associated survival. This model holds promise for differentiating prognosis and improving personalized therapeutic strategies for pRCC in clinical practice.PMID:38639274 | DOI:10.2174/0113862073303084240403051346 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 19, 2024 Category: Chemistry Authors: Yidong Zhu Xiaoyi Jin Jun Liu Source Type: research
Integrated Bioinformatics and Experimental Validation to Identify a Disulfidptosis-Related lncRNA Model for Prognostic Prediction in Papillary Renal Cell Carcinoma
CONCLUSION: This study successfully established and validated a novel disulfidptosis-related prediction model. The findings suggest the potential involvement of immune-related pathways in lncRNA signature-associated survival. This model holds promise for differentiating prognosis and improving personalized therapeutic strategies for pRCC in clinical practice.PMID:38639274 | DOI:10.2174/0113862073303084240403051346 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 19, 2024 Category: Chemistry Authors: Yidong Zhu Xiaoyi Jin Jun Liu Source Type: research
Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors
ConclusionsThe present study emphasizes the prognostic potential of early CRP kinetics in CPI-treated mRCC. As a standard laboratory parameter, CRP can be easily implemented into clinical routine to facilitate therapy monitoring. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 19, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1567: Discovery of Novel Potential Prognostic Markers and Targeted Therapy to Overcome Chemotherapy Resistance in an Advanced-Stage Wilms Tumor
In this study, we aimed to discover potential mutation markers and drug targets associated with chemotherapy resistance in advanced-stage WT. We performed exome sequencing to detect somatic mutations and molecular targets in 43 WT samples, comprising 26 advanced-stage WTs, of which 7 cases were chemotherapy-resistant. Our analysis revealed four genes (ALPK2, C16orf96, PRKDC, and SVIL) that correlated with chemotherapy resistance and reduced disease-free survival in advanced-stage WT. Additionally, we identified driver mutations in 55 genes within the chemotherapy-resistant group, including 14 druggable cancer driver genes....
Source: Cancers - April 19, 2024 Category: Cancer & Oncology Authors: Pongsakorn Choochuen Natakorn Nokchan Natthapon Khongcharoen Wison Laochareonsuk Komwit Surachat Thirachit Chotsampancharoen Thanit Sila Sangkhathat Tags: Article Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
